CELLIVITY is available to adults only. Supplement pages are general product information; peptide records are not a sales offer and are not for human use.
Age confirmation is a declaration, not identity verification. Restricted research access still requires separate professional eligibility checks.Privacy and legal notice ↗
Open full-size image ↗Packaging concept; the selected format is shown below.Selected format: 15 mg
This image is a CELLIVITY packaging concept. Current stock arrived in clear vials without individual labels; product details are on the outer box of 10 vials. Packaging for your selected quantity will be confirmed when you enquire.
CELLIVITY PEPTIDE LABS · CEL-P-MOT-001
MOTS-c
Lyophilised research-vial concept
For laboratory research only · Not intended for human or veterinary use.
THAILAND LAUNCH PRICE฿2,25015 mg · per vial · tax and delivery confirmed at enquiry
Received · batch documentation under reviewAvailability is confirmed for this exact format before any commitment.
MOTS-c is a short peptide encoded within mitochondrial 12S ribosomal RNA and studied as a possible signal between mitochondrial and cellular metabolism. Most findings are preclinical, making it a mechanism-led research topic rather than an established therapy.
Research focus
Mitochondrial-derived peptide biology and cellular stress adaptation.
Current evidence context
Preclinical findings do not establish human therapeutic efficacy. Human drug-exposure and long-term safety information remain insufficient for a consumer longevity conclusion.
Questions this record follows
How does MOTS-c signalling change under metabolic or cellular stress?
Which preclinical findings reproduce across models and laboratories?
What human exposure, pharmacology, immunogenicity and safety data are missing?
Follow the sources
Registry entries identify reference substances. Literature links describe research and do not certify this product or its batch.
Request current availability for a lawful institutional, analytical or laboratory purpose. We confirm the exact presentation, price, batch and document state before any next step.
Exact presentation review
Jurisdiction and purpose check
Batch-document confirmation
No medical or human-use guidance
SELECTED PRODUCTMOTS-cCEL-P-MOT-001 · response after manual review
MOTS-c: before you enquire
What exactly does the selected format mean?＋
The mg or IU value is the declared material content per vial; it is not the container volume. Your selected presentation and quantity are saved with your enquiry. The final price is confirmed in the response.
Which batch will be supplied?＋
The specific batch and its documents are confirmed in the response. Files shown here may be supplier reference samples; the current record does not yet contain a qualified CELLIVITY lot dossier.
When can it arrive in Thailand?＋
For confirmed local stock, the planned window is 2–3 working days in Thailand. Pattaya timing is agreed directly. Incoming or specially sourced products have a separate estimate, confirmed before a commitment.
Can I enquire about several products together?＋
Yes. Add each format and quantity to the cart, then send one availability enquiry. Your selected items are kept together for review.
CELLIVITY
MOTS-c
CEL-P-MOT-001 · 10 mg / 15 mg / 40 mg
MOTS-c is a short peptide encoded within mitochondrial 12S ribosomal RNA and studied as a possible signal between mitochondrial and cellular metabolism. Most findings are preclinical, making it a mechanism-led research topic rather than an established therapy.
Mitochondrial-derived peptide biology and cellular stress adaptation.
Other names
MOTS-c · mitochondrial open reading frame of the 12S rRNA-c
PubChem CID
146675088
CAS number
1627580-64-6
Molecular formula
C101H152N28O22S2
Molecular weight
2174.6 g/mol
Peptide length
16 amino acids
Compound class
Mitochondrial-derived peptide
Follow the sources
Preclinical findings do not establish human therapeutic efficacy. Human drug-exposure and long-term safety information remain insufficient for a consumer longevity conclusion.
How does MOTS-c signalling change under metabolic or cellular stress?
Which preclinical findings reproduce across models and laboratories?
What human exposure, pharmacology, immunogenicity and safety data are missing?
